logo
logo
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

NASDAQ•DAWN
CEO: Dr. Jeremy Bender M.B.A., Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-05-27
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
連絡先情報
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, 94005, United States
650-484-0899
dayonebio.com
時価総額
$1.17B
PER (TTM)
-7.7
34.3
配当利回り
--
52週高値
$13.20
52週安値
$5.64
52週レンジ
76%
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$39.80M-57.56%
直近4四半期の推移

EPS

-$0.19-150.00%
直近4四半期の推移

フリーCF

-$5.81M+16.78%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

OJEMDA US Product Sales Net product revenue reached $102.6M for nine months, surging 263.0% due to successful US commercial launch of OJEMDA.
Operations Loss Significantly Reduced Loss from operations improved 34.0% to $100.3M for nine months, driven by lower R&D spending post-milestone payments.
R&D Expenses Decrease Nine-month R&D expenses fell 35.4% to $107.2M, reflecting reduced license payments and winding down VRK1 program.
Cash Reserves Decline Cash and equivalents decreased to $43.3M as of September 30, 2025, down from $125.0M at year-end 2024.

リスク要因

Revenue Highly Customer Concentrated Nine-month product revenue heavily reliant on two customers, accounting for 98.3% of total net product revenue.
Expecting Continued Operating Losses Incurred $86.0M net loss for nine months; expects continued losses for foreseeable future, requiring additional capital.
Clinical Trial Outcomes Uncertain Future success depends on favorable results in ongoing pivotal Phase 3 FIREFLY-2 trial; failure risks reputation and business.
Intellectual Property Litigation Risk Reliance on licensed IP means disputes or challenges could impair rights, leading to costly litigation and business harm.

見通し

Advance Tovorafenib Pipeline Trials Continue FIREFLY-2 Phase 3 trial enrollment for front-line pLGG; DAY301 Phase 1a/b trial ongoing.
Need Additional Financing Current liquidity sufficient for twelve months; anticipates needing additional capital to fund planned clinical development programs.
Maximize Ipsen Commercialization Future revenue tied to successful ex-US commercialization by Ipsen, including milestone payments and tiered royalties.
Retain Key Scientific Personnel Focus on retaining executive officers and key employees amid fierce competition in the San Francisco Bay Area talent pool.

同業比較

売上高 (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Akebia Therapeutics, Inc.AKBA
$225.07M
+32.5%
Valneva SEVALN
$198.55M
+13.5%

粗利益率 (最新四半期)

Arvinas, Inc.ARVN
100.0%
+0.0pp
Astria Therapeutics, Inc.ATXS
100.0%
+0.0pp
Day One Biopharmaceuticals, Inc.DAWN
88.7%
-9.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ERAS$3.72B-26.7-33.1%11.5%
TERN$3.40B-36.7-30.0%0.3%
OLMA$1.78B-12.9-41.5%1.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
10.9%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月24日
|
EPS:-$0.15
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $39.80M-57.6%
    |
    EPS: $-0.19-150.0%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $33.91M+313.9%
    |
    EPS: $-0.29+473.1%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $30.76M+0.0%
    |
    EPS: $-0.35-51.4%
    予想を上回る

  • Form 10-K/A - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月6日|
    売上高: $131.16M+0.0%
    |
    EPS: $-1.02+57.0%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|修正版データを参照

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月30日|
    売上高: $93.76M+0.0%
    |
    EPS: $0.38-170.4%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月2日|
    売上高: $8.19M+0.0%
    |
    EPS: $-0.05-91.7%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.72+46.9%
    不明